Price$0.20-1.49 (-88.44%)
2025-07-082025-10-08
Latest news
25 items- SECSEC Form EFFECT filed by ESSA Pharma Inc.EFFECT - ESSA Pharma Inc. (0001633932) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.SCHEDULE 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.SCHEDULE 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
- SECSEC Form 15-12G filed by ESSA Pharma Inc.15-12G - ESSA Pharma Inc. (0001633932) (Filer)
- INSIDERPresident and CEO Parkinson David Ross returned 65,675 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ESSA Pharma Inc. (0001633932) (Issuer)
- INSIDERChief Financial Officer Wood David S. returned 33,343 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ESSA Pharma Inc. (0001633932) (Issuer)
- INSIDERDirector Berger Franklin M returned 784,404 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ESSA Pharma Inc. (0001633932) (Issuer)
- INSIDERDirector Glickman Richard M returned 43,240 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ESSA Pharma Inc. (0001633932) (Issuer)
- INSIDERDirector Requadt Scott returned 30,002 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ESSA Pharma Inc. (0001633932) (Issuer)
- INSIDERDirector Martin John Alexander returned 14,299 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ESSA Pharma Inc. (0001633932) (Issuer)
- INSIDERDirector Thorell Marella returned 2,881 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ESSA Pharma Inc. (0001633932) (Issuer)
- SECSEC Form POS AM filed by ESSA Pharma Inc.POS AM - ESSA Pharma Inc. (0001633932) (Filer)
- SECSEC Form S-8 POS filed by ESSA Pharma Inc.S-8 POS - ESSA Pharma Inc. (0001633932) (Filer)
- SECSEC Form S-8 POS filed by ESSA Pharma Inc.S-8 POS - ESSA Pharma Inc. (0001633932) (Filer)
- SECSEC Form S-8 POS filed by ESSA Pharma Inc.S-8 POS - ESSA Pharma Inc. (0001633932) (Filer)
- SECSEC Form S-8 POS filed by ESSA Pharma Inc.S-8 POS - ESSA Pharma Inc. (0001633932) (Filer)
- SECSEC Form S-8 POS filed by ESSA Pharma Inc.S-8 POS - ESSA Pharma Inc. (0001633932) (Filer)
- INSIDERSEC Form 4 filed by Large owner Bvf Partners L P/Il4 - ESSA Pharma Inc. (0001633932) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by ESSA Pharma Inc.SCHEDULE 13D/A - ESSA Pharma Inc. (0001633932) (Subject)
- SECSEC Form 25-NSE filed by ESSA Pharma Inc.25-NSE - ESSA Pharma Inc. (0001633932) (Subject)
- PRESSA Announces Completion of Arrangement with XenoTherapeuticsSOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada, Oct. 9, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ:EPIX) ("ESSA" or the "Company") today announced the completion of XenoTherapeutics' ("Xeno") previously announced acquisition of ESSA (the "Acquisition"). Xeno Acquisition Corp., a wholly owned subsidiary of Xeno, has acquired all of the outstanding common shares of ESSA (the "Common Shares") for approximately US$0.1242 per Common Share, plus one contingent value right ("CVR") per Common Share, which CVR represents the right to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the Acquisition. The potential CVR payment of US$0
- SECESSA Pharma Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Other Events, Financial Statements and Exhibits8-K - ESSA Pharma Inc. (0001633932) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.SCHEDULE 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
- SECESSA Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - ESSA Pharma Inc. (0001633932) (Filer)
- PRESSA Securityholders Approve Acquisition by XenoTherapeuticsSOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, Oct. 6, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ:EPIX) ("ESSA" or the "Company") is pleased to announce that its Securityholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the "Common Shares" and the holders of such Common Shares, the "Shareholders") by XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company, by way of a statutory plan of arrangement (the "Transaction" or the "Arrangement") at the special meeting of Securityholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 99.83% of the votes cast by S
EPIX FAQ
6 questionsWhat does ESSA Pharma Inc. do?
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.Where does EPIX stock trade?
ESSA Pharma Inc. (EPIX) is listed on NASDAQ.What sector and industry is EPIX in?
ESSA Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about EPIX?
ESSA Pharma Inc. has had 5 recent analyst actions on file. The most recent action was from Jefferies: Hold on 2024-11-04.What companies are similar to EPIX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare EPIX side-by-side with any of them on Quantisnow.How can I track EPIX on Quantisnow?
Quantisnow aggregates ESSA Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EPIX to receive live email and push alerts on every new disclosure.